In-depth Analysis of the HIV Reservoir Confirms Effectiveness and Safety of Dolutegravir/Lamivudine in a Phase 4 Randomized Controlled Switch Trial (RUMBA)
Marie‐Angélique De Scheerder(Ghent University Hospital), Linos Vandekerckhove(Ghent University Hospital), Els Caluwé(Ghent University Hospital), Stefanie De Buyser(Ghent University), Evy Blomme(Ghent University Hospital), Maja Kiselinova(Ghent University Hospital), Sarah Gerlo(University College Ghent), Loïc Schrooyen(Ghent University Hospital), Evelien De Smet(Ghent University Hospital), Maxime Verschoore(Inserm), Sophie Vanherrewege(Ghent University Hospital), Bram Van Den Eeckhout(Ghent University), Mareva Delporte(Ghent University Hospital), Sophie Degroote(Ghent University Hospital), Camilla Muccini(Vita-Salute San Raffaele University), Lara Vincke(Ghent University Hospital), Wim Trypsteen(Ghent University Hospital)
Cited by 8
Related Papers
The Digital MIQE Guidelines Update: Minimum Information for Publication of Quantitative Digital PCR Experiments for 2020
|Clinical Chemistry|2020|501
Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021
|Nature Medicine|2021|367
On the whereabouts of SARS-CoV-2 in the human body: A systematic review
|PLoS Pathogens|2020|231
Correction: Corrigendum: Differential expression of lncRNAs during the HIV replication cycle: an underestimated layer in the HIV-host interplay
|Scientific Reports|2017|174
The RNA Atlas expands the catalog of human non-coding RNAs
|Nature Biotechnology|2021|163